Fluorine in medicinal chemistry.
暂无分享,去创建一个
[1] N. Thornberry,et al. Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: close analogs of JANUVIA (sitagliptin phosphate). , 2007, Bioorganic & medicinal chemistry letters.
[2] Anna Vulpetti,et al. Design and NMR-based screening of LEF, a library of chemical fragments with different local environment of fluorine. , 2009, Journal of the American Chemical Society.
[3] John Sharkey,et al. Acquired QT interval prolongation and HERG: implications for drug discovery and development. , 2004, European journal of pharmacology.
[4] C. Stout,et al. The reaction of fluorocitrate with aconitase and the crystal structure of the enzyme-inhibitor complex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[5] Bruce E. Smart,et al. Fluorine substituent effects (on bioactivity) , 2001 .
[6] I. Hayakawa,et al. (Fluorocyclopropyl)quinolones. 2. Synthesis and Stereochemical structure-activity relationships of chiral 7-(7-amino-5-azaspiro[2.4]heptan-5-yl)-1-(2-fluorocyclopropyl)quinolone antibacterial agents. , 1994, Journal of medicinal chemistry.
[7] A. Vulpetti,et al. Fluorine as a hydrogen-bond acceptor: experimental evidence and computational calculations. , 2014, Chemistry.
[8] Guangtao Li,et al. Palladium‐Catalyzed CF Bond Formation via Directed CH Activation , 2014 .
[9] Varinder K. Aggarwal,et al. Science of Synthesis , 2005 .
[10] J. Ponto. The Handbook of Radiopharmaceuticals , 1996 .
[11] D. Halpern. Fluorinated Inhalation Anesthetics , 1994 .
[12] Chun Xing Li,et al. Improving metabolic stability of phosphodiesterase-4 inhibitors containing a substituted catechol: prevention of reactive intermediate formation and covalent binding. , 2002, Bioorganic & medicinal chemistry letters.
[13] J. B. Buckton,et al. Synthesis and structure-activity relationships in a series of antiinflammatory corticosteroid analogues, halomethyl androstane-17 beta-carbothioates and -17 beta-carboselenoates. , 1994, Journal of medicinal chemistry.
[14] C. Swain,et al. Piperidine-ether based hNK1 antagonists 1: Determination of the relative and absolute stereochemical requirements , 1994 .
[15] N. Thornberry,et al. Chapter 7 Case History: JANUVIA™ (Sitagliptin), a Selective Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes , 2007 .
[16] A. Bell,et al. Novel antifungal 2-aryl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol derivatives with high activity against Aspergillus fumigatus , 1996 .
[17] Alan Wheeldon,et al. 1-Phenyl-8-azabicyclo[3.2.1]octane ethers: a novel series of neurokinin (NK1) antagonists. , 2006, Bioorganic & medicinal chemistry letters.
[18] R. Rosenfeld. Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[19] P. Coleman,et al. Kinesin spindle protein (KSP) inhibitors. Part V: discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by beta-fluorination to overcome cellular efflux by P-glycoprotein. , 2007, Bioorganic & medicinal chemistry letters.
[20] A. Slawin,et al. 3-Fluoro-N-methyl-D-aspartic acid (3F-NMDA) stereoisomers as conformational probes for exploring agonist binding at NMDA receptors. , 2012, Chemistry.
[21] P. Leeson,et al. The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.
[22] F. Diederich,et al. Fluorine in Pharmaceuticals: Looking Beyond Intuition , 2007, Science.
[23] E. Carreira,et al. On the polarity of partially fluorinated methyl groups , 2013 .
[24] N. Jackson,et al. Special Feature Organo-Fluorine Chemical Science , 2012 .
[25] M. Sweeney,et al. Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials , 2007, Expert opinion on drug metabolism & toxicology.
[26] D. Hodgson,et al. Sodium monofluoroacetate (Compound 1080) poisoning in dogs. , 2005, Australian veterinary journal.
[27] H. Rzepa,et al. The preferred conformation of α-fluoroamides , 1999 .
[28] M. Rowley. 3‐(4‐Fluoropiperidin‐3‐yl)‐2‐phenylindoles as High Affinity, Selective, and Orally Bioavailable h5‐HT2A Receptor Antagonists. , 2001 .
[29] Steven V. Fox,et al. Pyridyl amides as potent inhibitors of T-type calcium channels. , 2011, Bioorganic & medicinal chemistry letters.
[30] Ramesh Kakarla,et al. Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B. , 2014, Journal of medicinal chemistry.
[31] P. Noakes,et al. The mode of toxic action of the pesticide Gliftor: The metabolism of 1,3‐difluoroacetone to (−)‐erythro‐fluorocitrate , 2001, Journal of biochemical and molecular toxicology.
[32] J. Howard,et al. Synthesis of monofluoro- and difluoro- methylenephosphonate analogues of sn-glycerol-3-phosphate as substrates for glycerol-3-phosphate dehydrogenase and the X-ray structure of the fluoromethylenephosphonate moiety , 1996 .
[33] A. Aronov. Ligand structural aspects of hERG channel blockade. , 2008, Current topics in medicinal chemistry.
[34] Shinji Tanaka,et al. Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 3: exploration of effective compounds in arthritis models. , 2011, Bioorganic & medicinal chemistry letters.
[35] You-Jung Park,et al. Discovery of potent and selective phenylalanine based dipeptidyl peptidase IV inhibitors. , 2004, Bioorganic & medicinal chemistry letters.
[36] M. Wilson,et al. Inhibitors of cholesterol biosynthesis. 1. trans-6-(2-pyrrol-1-ylethyl)-4-hydroxypyran-2-ones, a novel series of HMG-CoA reductase inhibitors. 1. Effects of structural modifications at the 2- and 5-positions of the pyrrole nucleus. , 1990, Journal of medicinal chemistry.
[37] Hanna Wójtowicz-Rajchel. Synthesis and applications of fluorinated nucleoside analogues , 2012 .
[38] C. K. Chu,et al. Fluorinated Nucleosides: Synthesis and Biological Implication. , 2008, Journal of fluorine chemistry.
[39] G. Scapin,et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2005, Journal of medicinal chemistry.
[40] Alexander G. Dossetter,et al. A matched molecular pair analysis of in vitro human microsomal metabolic stability measurements for heterocyclic replacements of di-substituted benzene containing compounds – identification of those isosteres more likely to have beneficial effects , 2012 .
[41] D G Reid,et al. Synthesis and evaluation of (+) and (-)-2,2-difluorocitrate as inhibitors of rat-liver ATP-citrate lyase and porcine-heart aconitase. , 1991, European journal of biochemistry.
[42] Wolfgang Guba,et al. β-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease. , 2013, Journal of medicinal chemistry.
[43] W. Bretz,et al. Red Marine Algae Lithothamnion calcareum Supports Dental Enamel Mineralization , 2023, Marine drugs.
[44] Marc C Nicklaus,et al. Experimental and structural evidence that herpes 1 kinase and cellular DNA polymerase(s) discriminate on the basis of sugar pucker. , 2004, Journal of the American Chemical Society.
[45] E. Stefánsson,et al. Topical drug delivery to the eye: dorzolamide , 2012, Acta ophthalmologica.
[46] A. Vulpetti,et al. Fluorine local environment: from screening to drug design. , 2012, Drug discovery today.
[47] J. Clader,et al. Discovery of 1‐(4‐Fluorophenyl)‐(3R)‐ [3‐(4‐fluorophenyl)‐(3S)‐hydroxypropyl] ‐(4S)‐(4‐hydroxyphenyl)‐2‐azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption. , 1998 .
[48] T. Maren,et al. A new class of carbonic anhydrase inhibitor. , 1993, The Journal of biological chemistry.
[49] C. Eason,et al. A 90-day toxicological evaluation of Compound 1080 (sodium monofluoroacetate) in Sprague-Dawley rats. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.
[50] C. George,et al. Comprehensive structural studies of 2',3'-difluorinated nucleosides: comparison of theory, solution, and solid state. , 2008, Journal of the American Chemical Society.
[51] P. Kirkpatrick,et al. Fresh from the pipeline. Ezetimibe. , 2003, Nature reviews. Drug discovery.
[52] N. Wood,et al. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[53] J. Humphrey. Medicinal chemistry of selective neurokinin-1 antagonists. , 2003, Current topics in medicinal chemistry.
[54] S. Harding. The human pharmacology of fluticasone propionate. , 1990, Respiratory medicine.
[55] K. Gibson,et al. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. , 2001, Bioorganic & medicinal chemistry letters.
[56] R. Young,et al. Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor. , 2002, Bioorganic & medicinal chemistry letters.
[57] G. Colombo,et al. Synthesis, structure and conformation of partially-modified retro- and retro-inverso psi[NHCH(CF3)]Gly peptides. , 2003, Chemistry.
[58] David J. Yang,et al. Handbook of Radiopharmaceuticals: Radiochemistry and Applications , 2004 .
[59] Choon‐Hong Tan,et al. Selective fluorination of alkyl C-H bonds via photocatalysis. , 2014, Chemical communications.
[60] François Diederich. Predicting and Tuning Physicochemical Properties in Lead Optimization: Amine Basicities , 2007 .
[61] Martin Stahl,et al. Fluorine in Medicinal Chemistry , 2004, Chembiochem : a European journal of chemical biology.
[62] M. Otto,et al. Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. , 2010, Journal of medicinal chemistry.
[63] H. Böhm,et al. Facilitating the Design of Fluorinated Drugs , 2009 .
[64] K. Wanner,et al. Methods and Principles in Medicinal Chemistry , 2007 .
[65] I. McLay,et al. X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. , 2008, Journal of medicinal chemistry.
[66] W. Zeng,et al. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase‐4 inhibitor, in healthy volunteers , 2007, Biopharmaceutics & drug disposition.
[67] Youwei Yan,et al. Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer. , 2008, Journal of medicinal chemistry.
[68] J. Domagala,et al. New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay. , 1986, Journal of medicinal chemistry.
[69] Carlos González,et al. Rigid 2',4'-difluororibonucleosides: synthesis, conformational analysis, and incorporation into nascent RNA by HCV polymerase. , 2014, The Journal of organic chemistry.
[70] Steven D. Brown,et al. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species , 1996, Antimicrobial agents and chemotherapy.
[71] C. Supuran,et al. New zinc binding motifs in the design of selective carbonic anhydrase inhibitors. , 2006, Mini reviews in medicinal chemistry.
[72] G. H. Phillipps. Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. , 1990, Respiratory medicine.
[73] F. R E D E R I C,et al. TOXICITY AND ACTION OF FLUENETHYL ACARICIDE AND RELATED COMPOUNDS IN THE MOUSE , HOUSEFLY AND TWOSPOTTED SPIDER MITE , 2022 .
[74] Niklas Blomberg,et al. Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules. , 2011, Bioorganic & medicinal chemistry letters.
[75] Desmond O'Connor,et al. 4-Fluorosulfonylpiperidines: selective 5-HT2A ligands for the treatment of insomnia. , 2005, Bioorganic & medicinal chemistry letters.
[76] B. Zhong,et al. Asymmetric synthesis of chiral organofluorine compounds: use of nonracemic fluoroiodoacetic acid as a practical electrophile and its application to the synthesis of monofluoro hydroxyethylene dipeptide isosteres within a novel series of HIV protease inhibitors. , 2001, Journal of the American Chemical Society.
[77] Guangtao Li,et al. Palladium‐Catalyzed C—F Bond Formation via Directed C—H Activation , 2014 .
[78] J. Kath,et al. The discovery of structurally novel CCR1 antagonists derived from a hydroxyethylene peptide isostere template. , 2004, Bioorganic & medicinal chemistry letters.
[79] A. Slawin,et al. Synthesis and Vanilloid Receptor (TRPV1) Activity of the Enantiomers of α‐Fluorinated Capsaicin , 2009, ChemBioChem.
[80] Victor E. Marquez,et al. HIV-1 REVERSE TRANSCRIPTASE CAN DISCRIMINATE BETWEEN TWO CONFORMATIONALLY LOCKED CARBOCYCLIC AZT TRIPHOSPHATE ANALOGUES , 1998 .
[81] S. Dworetzky,et al. Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition. , 2003, Journal of medicinal chemistry.
[82] H. Davis,et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. , 1997, The Journal of pharmacology and experimental therapeutics.
[83] A. Robichaud,et al. The next generation of PDE4 inhibitors. , 2001, Current opinion in chemical biology.
[84] C. D. Boone,et al. Structural study of interaction between brinzolamide and dorzolamide inhibition of human carbonic anhydrases. , 2013, Bioorganic & medicinal chemistry.
[85] Jeremy N. Burrows,et al. Fluorine Modulates Species Selectivity in the Triazolopyrimidine Class of Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors , 2014, Journal of medicinal chemistry.
[86] B. Matuszewski,et al. Simultaneous determination of Aprepitant and two metabolites in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection. , 2004, Journal of pharmaceutical and biomedical analysis.
[87] C. Swain,et al. Piperidine-ether based hNK1 antagonists 2: Investigation of the effect of N-substitution , 1995 .
[88] Peter W. Kenny,et al. Prediction of hydrogen bond basicity from computed molecular electrostatic properties: implications for comparative molecular field analysis , 1994 .
[89] David A. Price,et al. Role of Physicochemical Properties and Ligand Lipophilicity Efficiency in Addressing Drug Safety Risks , 2010 .
[90] J. Falgueyret,et al. Difluoroethylamines as an amide isostere in inhibitors of cathepsin K. , 2005, Bioorganic & medicinal chemistry letters.
[91] Z. Parandoosh,et al. Interaction of glucocorticoid analogues with the human glucocorticoid receptor , 1992, The Journal of Steroid Biochemistry and Molecular Biology.
[92] J. Deisenhofer,et al. Structural Mechanism for Statin Inhibition of HMG-CoA Reductase , 2001, Science.
[93] K. Richardson. The discovery of fluconazole , 1996 .
[94] Daniel Oehlrich,et al. The evolution of amidine-based brain penetrant BACE1 inhibitors. , 2014, Bioorganic & medicinal chemistry letters.
[95] A. Liljas,et al. The structure of a complex between carbonic anhydrase II and a new inhibitor, trifluoromethane sulphonamide , 1994, FEBS letters.
[96] C. Bayly,et al. Trifluoroethylamines as amide isosteres in inhibitors of cathepsin K. , 2006, Bioorganic & Medicinal Chemistry Letters.
[97] R. S. Rogers,et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). , 1997, Journal of medicinal chemistry.
[98] E. F. Sabo,et al. 9α-FLUORO DERIVATIVES OF CORTISONE AND HYDROCORTISONE , 1954 .
[99] M. Palem-Vliers,et al. Role of hydrophobic effects and polar groups in steroid-mineralocorticoid receptor interactions. , 1983, Journal of steroid biochemistry.
[100] Bernd Kuhn,et al. Molecular recognition of ligands in dipeptidyl peptidase IV. , 2007, Current topics in medicinal chemistry.
[101] Chuo Chen,et al. Vanadium-Catalyzed C(sp3)-H Fluorination Reactions. , 2014, Organic chemistry frontiers : an international journal of organic chemistry.
[102] Ernesto Callegari,et al. A comprehensive listing of bioactivation pathways of organic functional groups. , 2005, Current drug metabolism.
[103] K. Ding,et al. Organic chemistry : breakthroughs and perspectives , 2012 .
[104] B. Jönsson,et al. Pharmacoeconomics , 2018, Indian Journal of Medical and Paediatric Oncology.
[105] D. Drucker,et al. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.
[106] C. R. Briggs,et al. The CF bond as a tool in the conformational control of amides , 2003 .
[107] A. Robichaud,et al. The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[108] D. O'Hagan. Understanding Organofluorine Chemistry. An Introduction to the C—F Bond , 2008 .
[109] Jonathan Greer,et al. The Three-dimensional Structures of Antagonistic and Agonistic Forms of the Glucocorticoid Receptor Ligand-binding Domain , 2003, Journal of Biological Chemistry.
[110] C. Swain,et al. Phenyl-glycinol based NK1 receptor antagonists — towards the minimum pharmacophore , 1995 .
[111] B. Graves,et al. Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors , 2011, Journal of medicinal chemistry.
[112] Organofluorine Chemistry: Deoxyfluorination Reagents for C—F Bond Synthesis , 2012 .
[113] François Diederich,et al. Orthogonal multipolar interactions in structural chemistry and biology. , 2005, Angewandte Chemie.
[114] J. Metzger,et al. Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist. , 1998, Journal of medicinal chemistry.
[115] C. Strader,et al. 2(S)-((3,5-bis(trifluoromethyl)benzyl)-oxy)-3(S)-phenyl-4- ((3-oxo-1,2,4-triazol-5-yl)methyl)morpholine (1): a potent, orally active, morpholine-based human neurokinin-1 receptor antagonist. , 1996, Journal of medicinal chemistry.
[116] A. MacGowan,et al. Development of the quinolones. , 2003, The Journal of antimicrobial chemotherapy.
[117] W. L. Mock,et al. Concerning the relative acidities of simple alcohols , 1990 .
[118] T. Willson,et al. Crystal Structure of the Glucocorticoid Receptor Ligand Binding Domain Reveals a Novel Mode of Receptor Dimerization and Coactivator Recognition , 2002, Cell.
[119] Richard I. Hartley,et al. Chirality , 2004, International Journal of Computer Vision.
[120] R. Chambers,et al. Fluorine in organic chemistry , 1973 .
[121] L. Hunter,et al. The C–F bond as a conformational tool in organic and biological chemistry , 2010, Beilstein journal of organic chemistry.
[122] D. Ehmann,et al. Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profile. , 2012, Journal of medicinal chemistry.
[123] G. Prakash,et al. Flourishing Frontiers in Organofluorine Chemistry , 2012 .
[124] W. Hagmann,et al. The many roles for fluorine in medicinal chemistry. , 2008, Journal of medicinal chemistry.
[125] A. Asai,et al. Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. , 2010, Journal of medicinal chemistry.
[126] Keith H. Gibson and. Studies Leading to the Identification of ZD1839 (Iressa): An Orally Active, Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Targeted to the Treatment of Cancer. , 2010 .
[127] P. Hajduk,et al. Statistical analysis of the effects of common chemical substituents on ligand potency. , 2008, Journal of medicinal chemistry.
[128] N. Thornberry,et al. Substituted piperazines as novel dipeptidyl peptidase IV inhibitors. , 2004, Bioorganic & medicinal chemistry letters.
[129] D. Tashkin. Roflumilast: the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD , 2014, Expert opinion on pharmacotherapy.
[130] Alexander G. Dossetter,et al. A statistical analysis of in vitro human microsomal metabolic stability of small phenyl group substituents, leading to improved design sets for parallel SAR exploration of a chemical series. , 2010, Bioorganic & medicinal chemistry.
[131] P. L. McCormack. Celecoxib , 2011, Drugs.
[132] Jimmy Wu. Review of recent advances in nucleophilic C–F bond-forming reactions at sp3 centers , 2014 .